← All Signals

🏥 FDA: Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles — Class II

healthcarebearishSource: FDA
90%Confidence
0Views
FDASource
2026-05-26Date

Summary

A compounding pharmacy error led to a TPN bag missing insulin, posing serious patient risk and highlighting quality control failures in sterile compounding. This could increase regulatory scrutiny on CAPS and similar compounding pharmacies, potentially impacting their contracts and reputation.

Actionable: Review exposure to Central Admixture Pharmacy Services and consider diversifying suppliers for compounded sterile products.

AI Confidence: 90%

Data Points

firmCentral Admixture Pharmacy Services, Inc (CAPS) Los Angeles
classificationClass II
statusOngoing
distributionCA
productTPN bag (patient specific), Rx# 11-4909703-0-1, Compound Volume 1660 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection, Central Admix

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now